Ibudilast (Ketas^®) in Meniere's Disease

Abstract

To assess the efficacy of Ibudilast in Meniere's desease, we randomly selected 15 patients with this desease seven males and eight females aged 30 - 73 years.
We administered three capsules of Ketas^® every day to these patients and investigated the following : 1) effect of treatment on vertigo, 2) effect of treatment on damage to the inner ear, 3) effect of treatment on recurrent attacks of vertigo. The effect of treatment on recurrent attacks of vertigo was evaluated by comparing the number of attacks a months after the start of treatment with the number before treatment.
Treatment reduced recurrent attacks of vertigo in 11 patients (73%).
No side effects were reported in this study.
We conclude that Ketas^® may be an effective drug for Meniere's disease.